Christine Nai-Mei Sang, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics | 8 | 2016 | 1070 | 1.060 |
Why?
|
| Neuralgia | 7 | 2024 | 615 | 0.980 |
Why?
|
| Hyperalgesia | 4 | 2017 | 532 | 0.780 |
Why?
|
| Pain | 11 | 2020 | 5073 | 0.740 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2020 | 370 | 0.700 |
Why?
|
| Diabetic Neuropathies | 4 | 2024 | 405 | 0.530 |
Why?
|
| Lidocaine | 2 | 2017 | 538 | 0.480 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 41 | 0.430 |
Why?
|
| Narcotic Antagonists | 1 | 2017 | 585 | 0.400 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2013 | 140 | 0.400 |
Why?
|
| Pain Measurement | 11 | 2021 | 3551 | 0.390 |
Why?
|
| Receptors, Kainic Acid | 2 | 2004 | 91 | 0.390 |
Why?
|
| Isoquinolines | 3 | 2004 | 352 | 0.390 |
Why?
|
| Amines | 1 | 2013 | 281 | 0.380 |
Why?
|
| Neuropeptides | 1 | 2016 | 944 | 0.350 |
Why?
|
| Receptors, AMPA | 2 | 2004 | 336 | 0.350 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 448 | 0.310 |
Why?
|
| Glycoproteins | 1 | 2016 | 2203 | 0.310 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 925 | 0.310 |
Why?
|
| Analgesics, Opioid | 4 | 2020 | 3808 | 0.300 |
Why?
|
| Sensation | 1 | 2009 | 337 | 0.290 |
Why?
|
| Pain Threshold | 3 | 2017 | 604 | 0.290 |
Why?
|
| Tetrazoles | 3 | 2004 | 909 | 0.290 |
Why?
|
| Capsaicin | 3 | 1998 | 231 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 1141 | 0.270 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2009 | 710 | 0.270 |
Why?
|
| Spinal Cord | 3 | 2017 | 1819 | 0.270 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2002 | 895 | 0.250 |
Why?
|
| Brain Concussion | 1 | 2017 | 1404 | 0.250 |
Why?
|
| Dextromethorphan | 2 | 2002 | 37 | 0.250 |
Why?
|
| Pain, Intractable | 1 | 2005 | 132 | 0.240 |
Why?
|
| Memantine | 1 | 2002 | 108 | 0.190 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 270 | 0.180 |
Why?
|
| Neurons, Afferent | 1 | 2003 | 498 | 0.180 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 271 | 0.160 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2018 | 43 | 0.160 |
Why?
|
| Fluoroscopy | 2 | 2002 | 947 | 0.160 |
Why?
|
| Succinylcholine | 1 | 2018 | 66 | 0.160 |
Why?
|
| Drug Synergism | 2 | 2017 | 1756 | 0.150 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2021 | 254 | 0.150 |
Why?
|
| Halothane | 1 | 2017 | 200 | 0.140 |
Why?
|
| Pain, Postoperative | 4 | 2017 | 1740 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 793 | 0.140 |
Why?
|
| Neurotensin | 1 | 2016 | 60 | 0.130 |
Why?
|
| Plasmids | 1 | 2021 | 2269 | 0.130 |
Why?
|
| Cervical Vertebrae | 1 | 2002 | 980 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2016 | 10766 | 0.130 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 556 | 0.130 |
Why?
|
| Injections, Spinal | 1 | 2016 | 318 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 8002 | 0.120 |
Why?
|
| Glycopyrrolate | 1 | 1994 | 32 | 0.120 |
Why?
|
| Priapism | 1 | 1994 | 28 | 0.120 |
Why?
|
| Penile Erection | 1 | 1994 | 100 | 0.120 |
Why?
|
| Double-Blind Method | 8 | 2024 | 12341 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 883 | 0.110 |
Why?
|
| Steroids | 4 | 2003 | 929 | 0.110 |
Why?
|
| Nerve Fibers | 1 | 1996 | 708 | 0.100 |
Why?
|
| Analgesia | 1 | 2017 | 461 | 0.100 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 574 | 0.100 |
Why?
|
| Migraine Disorders | 1 | 2004 | 1703 | 0.100 |
Why?
|
| Skin | 2 | 2003 | 4484 | 0.090 |
Why?
|
| Injections, Epidural | 2 | 2002 | 201 | 0.090 |
Why?
|
| Humans | 38 | 2024 | 761572 | 0.090 |
Why?
|
| Pemphigus | 1 | 1991 | 107 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2017 | 1036 | 0.080 |
Why?
|
| Fibromuscular Dysplasia | 1 | 1989 | 55 | 0.080 |
Why?
|
| Analgesia, Epidural | 2 | 2003 | 332 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 962 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2000 | 1667 | 0.080 |
Why?
|
| Contrast Media | 1 | 2002 | 5311 | 0.080 |
Why?
|
| Renal Artery | 1 | 1989 | 351 | 0.070 |
Why?
|
| TRPV Cation Channels | 1 | 2009 | 244 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 1994 | 1166 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 1421 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2024 | 64684 | 0.070 |
Why?
|
| Anesthesiology | 1 | 2017 | 1120 | 0.070 |
Why?
|
| Nociceptors | 2 | 2002 | 461 | 0.070 |
Why?
|
| Adiposis Dolorosa | 1 | 2006 | 11 | 0.070 |
Why?
|
| Erythema Nodosum | 1 | 2006 | 32 | 0.070 |
Why?
|
| Anesthesia | 1 | 2017 | 1595 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 3220 | 0.060 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2007 | 186 | 0.060 |
Why?
|
| Lipomatosis | 1 | 2006 | 112 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1989 | 748 | 0.060 |
Why?
|
| Middle Aged | 15 | 2024 | 220920 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4853 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2005 | 641 | 0.060 |
Why?
|
| Laminectomy | 2 | 2002 | 225 | 0.060 |
Why?
|
| Thiophenes | 1 | 2007 | 569 | 0.050 |
Why?
|
| Adult | 16 | 2024 | 221203 | 0.050 |
Why?
|
| Neurofibromatosis 2 | 1 | 2005 | 385 | 0.050 |
Why?
|
| Peripheral Nervous System | 1 | 2002 | 151 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2005 | 1416 | 0.050 |
Why?
|
| Male | 17 | 2024 | 360842 | 0.050 |
Why?
|
| Diffusion | 1 | 2002 | 814 | 0.040 |
Why?
|
| Ketorolac | 1 | 2000 | 94 | 0.040 |
Why?
|
| Neurilemmoma | 1 | 2005 | 526 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 9469 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2018 | 2767 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 554 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6346 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2002 | 957 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2002 | 590 | 0.040 |
Why?
|
| Professional Competence | 1 | 2002 | 431 | 0.040 |
Why?
|
| Oral Surgical Procedures | 1 | 2000 | 166 | 0.040 |
Why?
|
| Malignant Hyperthermia | 1 | 2018 | 71 | 0.040 |
Why?
|
| Spasm | 1 | 2018 | 130 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 3416 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2017 | 50 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2003 | 1736 | 0.040 |
Why?
|
| Aged | 7 | 2024 | 169310 | 0.040 |
Why?
|
| Tooth Extraction | 1 | 1998 | 229 | 0.040 |
Why?
|
| Education | 1 | 2020 | 537 | 0.040 |
Why?
|
| Neck | 1 | 2002 | 734 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 1998 | 517 | 0.040 |
Why?
|
| Placebos | 1 | 2021 | 1667 | 0.030 |
Why?
|
| Female | 15 | 2024 | 392686 | 0.030 |
Why?
|
| Hyperkalemia | 1 | 2018 | 233 | 0.030 |
Why?
|
| Digitoxin | 1 | 1975 | 19 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 2691 | 0.030 |
Why?
|
| Acute Disease | 2 | 2004 | 7237 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2004 | 6228 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 6312 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 173 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 1975 | 108 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15843 | 0.030 |
Why?
|
| Cadmium | 1 | 1975 | 214 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 539 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 452 | 0.030 |
Why?
|
| Ketamine | 1 | 2000 | 519 | 0.030 |
Why?
|
| Mercury | 1 | 1975 | 290 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 1994 | 233 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1994 | 1379 | 0.030 |
Why?
|
| Animals | 8 | 2018 | 168467 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1998 | 1440 | 0.020 |
Why?
|
| Drug Industry | 1 | 2018 | 788 | 0.020 |
Why?
|
| Anesthesia, Spinal | 1 | 1994 | 280 | 0.020 |
Why?
|
| Zinc | 1 | 1975 | 690 | 0.020 |
Why?
|
| Drug Approval | 1 | 2018 | 814 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 9319 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 2273 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18253 | 0.020 |
Why?
|
| Piperidines | 1 | 1998 | 1656 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1664 | 0.020 |
Why?
|
| Ulcer | 1 | 1991 | 204 | 0.020 |
Why?
|
| Quality of Life | 2 | 2021 | 13367 | 0.020 |
Why?
|
| Nerve Block | 1 | 1996 | 706 | 0.020 |
Why?
|
| Pharyngitis | 1 | 1991 | 220 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 1991 | 241 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 10212 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 1989 | 192 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1989 | 335 | 0.020 |
Why?
|
| Sex Factors | 1 | 2002 | 10553 | 0.020 |
Why?
|
| United States | 4 | 2020 | 72335 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 58986 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 1989 | 554 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2006 | 30 | 0.020 |
Why?
|
| Panniculitis | 1 | 2006 | 45 | 0.020 |
Why?
|
| Streptomyces griseus | 1 | 1975 | 5 | 0.020 |
Why?
|
| Hemerythrin | 1 | 1975 | 5 | 0.020 |
Why?
|
| Hexosaminidases | 1 | 1975 | 45 | 0.020 |
Why?
|
| Age Factors | 2 | 2002 | 18398 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1975 | 66 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2006 | 132 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 2 | 1999 | 1122 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 15266 | 0.020 |
Why?
|
| Metalloproteins | 1 | 1975 | 101 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2164 | 0.020 |
Why?
|
| Time Factors | 3 | 2003 | 39970 | 0.020 |
Why?
|
| Lipoma | 1 | 2006 | 293 | 0.010 |
Why?
|
| Brain Mapping | 1 | 1999 | 6635 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1989 | 1328 | 0.010 |
Why?
|
| Research Design | 1 | 2000 | 6180 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 20099 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1998 | 2496 | 0.010 |
Why?
|
| Respiration | 1 | 1989 | 1657 | 0.010 |
Why?
|
| beta-Endorphin | 1 | 2002 | 43 | 0.010 |
Why?
|
| Codeine | 1 | 2002 | 51 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1983 | 94 | 0.010 |
Why?
|
| Brain | 2 | 1999 | 27120 | 0.010 |
Why?
|
| Epidural Space | 1 | 2002 | 122 | 0.010 |
Why?
|
| Neuroma, Acoustic | 1 | 2005 | 459 | 0.010 |
Why?
|
| Lens, Crystalline | 1 | 1983 | 389 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 12975 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 2002 | 277 | 0.010 |
Why?
|
| Glutathione | 1 | 1983 | 583 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 1975 | 1154 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1975 | 730 | 0.010 |
Why?
|
| Oxygen Radioisotopes | 1 | 1999 | 75 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2002 | 554 | 0.010 |
Why?
|
| Posture | 1 | 2002 | 957 | 0.010 |
Why?
|
| Cataract | 1 | 1983 | 832 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 5972 | 0.010 |
Why?
|
| Carbon Dioxide | 2 | 1998 | 1147 | 0.010 |
Why?
|
| Digitoxigenin | 1 | 1975 | 9 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 1496 | 0.010 |
Why?
|
| Carotid Body | 1 | 1975 | 26 | 0.010 |
Why?
|
| Vibration | 1 | 1998 | 328 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 213 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1975 | 137 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 2218 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 2002 | 1174 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1999 | 829 | 0.010 |
Why?
|
| Kinetics | 2 | 1998 | 6374 | 0.010 |
Why?
|
| NADP | 1 | 1975 | 227 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 6766 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 36429 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3312 | 0.010 |
Why?
|
| Kidney | 1 | 1989 | 7047 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 1371 | 0.010 |
Why?
|
| Low Back Pain | 1 | 2002 | 984 | 0.010 |
Why?
|
| Protein Conformation | 2 | 1975 | 3968 | 0.010 |
Why?
|
| Data Collection | 1 | 2002 | 3322 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 80646 | 0.010 |
Why?
|
| Perception | 1 | 1999 | 1197 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1999 | 2257 | 0.010 |
Why?
|
| Smoking | 1 | 1989 | 9053 | 0.010 |
Why?
|
| Affect | 1 | 1999 | 1486 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1989 | 22176 | 0.010 |
Why?
|
| Species Specificity | 2 | 1975 | 2414 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1999 | 1769 | 0.010 |
Why?
|
| Cattle | 1 | 1975 | 3849 | 0.010 |
Why?
|
| Hypertension | 1 | 1989 | 8540 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1975 | 1569 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1999 | 2727 | 0.010 |
Why?
|
| Oxygen | 2 | 1998 | 4227 | 0.000 |
Why?
|
| Binding Sites | 1 | 1975 | 6056 | 0.000 |
Why?
|
| Cnidaria | 1 | 1975 | 14 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1975 | 3769 | 0.000 |
Why?
|
| Fucose | 1 | 1975 | 122 | 0.000 |
Why?
|
| Rats | 2 | 1983 | 23741 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1989 | 15501 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1975 | 406 | 0.000 |
Why?
|
| Lens Cortex, Crystalline | 1 | 1983 | 21 | 0.000 |
Why?
|
| Glutathione Disulfide | 1 | 1983 | 33 | 0.000 |
Why?
|
| Protein Binding | 1 | 1975 | 9353 | 0.000 |
Why?
|
| Computers | 1 | 1975 | 593 | 0.000 |
Why?
|
| Heart | 1 | 1975 | 4404 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1983 | 2088 | 0.000 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1983 | 210 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1975 | 3076 | 0.000 |
Why?
|
| Carotid Sinus | 1 | 1975 | 44 | 0.000 |
Why?
|
| Vagotomy | 1 | 1975 | 83 | 0.000 |
Why?
|
| Chemoreceptor Cells | 1 | 1975 | 89 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1975 | 5439 | 0.000 |
Why?
|
| Ventricular Function | 1 | 1975 | 406 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1975 | 930 | 0.000 |
Why?
|
| Pressure | 1 | 1975 | 1154 | 0.000 |
Why?
|
| Perfusion | 1 | 1975 | 1373 | 0.000 |
Why?
|
| Dogs | 1 | 1975 | 3839 | 0.000 |
Why?
|
| Heart Rate | 1 | 1975 | 4195 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1975 | 8481 | 0.000 |
Why?
|